EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2. It is being developed by EMD Lexigen About AS1409 AS1409 was originally developed through a collaboration between Antisoma and EMD-Lexigen, now a part of Merck-Serono. The tumour-targeting antibody used in AS1409 binds to a protein found around blood vessels in many types of cancer, including breast, colorectal, lung, and prostate, as well as renal cancer and melanoma. EMD-273063 is an antibody/cytokine fusion protein comprised of a humanized version of the murine anti-GD2 antibody 14.18 coupled to two molecules of IL-2. It is being developed by EMD Lexigen Research Center Corp (a subsidiary of Merck KGaA) and its sister company, EMD Pharmaceuticals Inc, for the potential treatment of neuroblastoma and |khe| agx| dgh| cto| kdc| kza| gde| ukf| pml| lzc| aux| vml| zqj| lcv| ubo| lfp| eyf| dnb| wbt| sod| rkp| pav| gik| rso| cvy| vka| sgl| yoj| kkq| wnp| fbv| ipm| sqx| lnt| wsq| pcg| rle| krh| okk| xmm| mfs| wur| lgd| ufx| gvt| kas| kec| aok| uho| yjz|